BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Long-term Debt
Borrowings due after more than one year.
BioAge Labs, Inc.NASDAQ: BIOA
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt rises 111.1% from a year ago
Long-term debt stood at $2.23M at the end of Q1 FY2026, up 111.1% from a year earlier and down 4.3% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.
Context
- Long-term debt amounted to 0.6% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
What to watch
Whether long-term debt keeps rising in the next quarterly balance sheet after a +111.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 2.33M USD
- Year-over-year change
- -6.9%
- 3-year CAGR
- +1.1%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.33M | -6.9% |
| FY2024 | 2024-12-31 | 2.5M | -69.5% |
| FY2023 | 2023-12-31 | 8.2M | +264.2% |
| FY2022 | 2022-12-31 | 2.25M | — |
Long-term Debt vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +111.1% is the highest of 5, against a peer median of -36.1%.
- Long-term debt amounts to 0.6% of total assets for BIOA, versus a peer median of 12.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$217.12M CAD | -27.6% | -26.1% | 19.4% | |
| Dec 2025 | $135.59M USD | — | — | 58.4% | |
| Mar 2026 | $47.18M USD | — | — | 31.6% | |
| Mar 2026 | $35.87M USD | -44.5% | +20.3% | 32.4% | |
| Mar 2026 | $12.74M USD | -1.9% | -15.5% | 12.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | $2.23M USD | +111.1% | +1.1% | 0.6% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | -36.1% | -15.5% | 12.9% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.